Breaking Down the Numbers: SCHK Aims for $36
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 10 2025
0mins
Source: NASDAQ.COM
ETF Performance Analysis: The Schwab 1000 Index ETF (SCHK) has an implied analyst target price of $35.59, indicating a potential upside of 9.95% from its current trading price of $32.37.
Notable Holdings with Upside: Key underlying holdings such as Venture Global Inc (VG), RadNet Inc (RDNT), and SPX Technologies Inc (SPXC) show significant upside potential, with VG expected to rise by 33.91%, RDNT by 10.81%, and SPXC by 10.41% based on analyst targets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDNT
Wall Street analysts forecast RDNT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.890
Low
86.00
Averages
90.17
High
95.00
Current: 52.890
Low
86.00
Averages
90.17
High
95.00
About RDNT
RadNet, Inc. is a national provider of fixed-site diagnostic imaging services in the United States. The Company has a network of 407 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. It provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. It is also a provider of AI-powered breast health solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alpha Wave Global Reduces RadNet Stake by 63,147 Shares
- Stake Reduction Details: According to an SEC filing dated May 14, 2026, Alpha Wave Global reduced its RadNet position by 63,147 shares in Q1, with an estimated trade value of approximately $4.31 million, indicating a cautious outlook on the company.
- Ownership Proportion Change: Following the reduction, Alpha Wave Global's stake in RadNet stands at 478,304 shares, representing 3.38% of its 13F AUM, reflecting a diminished confidence in the company's future performance.
- Financial Performance Overview: RadNet's latest earnings report indicates a 22.1% year-over-year revenue increase to $575.6 million, with adjusted EBITDA rising 36.3% to $63.3 million, showcasing strong growth potential in its imaging business.
- Market Performance Analysis: As of May 13, 2026, RadNet shares were priced at $52.98, down 12.5% over the past year, significantly underperforming the S&P 500 by 38.9 percentage points, prompting investors to closely monitor its future market performance.
See More
RadNet Hosts Free Webinar on Men's Health Issues
- Focus on Men's Health: RadNet will host a free webinar on June 13, 2026, aimed at raising public awareness about significant men's health issues, particularly coronary artery disease, prostate cancer, and lung cancer, which pose major threats to American men's health.
- Disease Statistics: Heart disease remains the leading cause of death among American men, with over 52% of men over 20 living with some form of cardiovascular disease, while prostate cancer affects 1 in 8 men, with more than 50% of the risk linked to genetics.
- Importance of Early Screening: The webinar will emphasize the critical role of early detection in improving health outcomes, recommending that men start screening for heart disease at age 40, prostate cancer at 45, and lung cancer at 50 to identify potential health issues promptly.
- Expert Speaker Lineup: The event will feature presentations from several medical experts, including Dr. Michael G. Coords, Medical Director in California, Dr. Randall Stenoien, Medical Director in Texas, and Dr. Evan Kaminer, Medical Director in New York, who will share the latest advancements and technologies in their respective fields to help participants better understand men's health issues.
See More
RadNet Reports Record Q1 2026 Earnings Amid Weather Challenges
- Record Performance: RadNet achieved record revenue and adjusted EBITDA in Q1 2026, despite an estimated $13 million revenue and $9 million EBITDA loss due to severe weather, demonstrating the company's resilience and sustained market demand even in challenging conditions.
- Significant Procedure Growth: PET/CT procedures increased by 35.2% year-over-year, with same-center growth of 14.7%, and 29.3% of procedural volume coming from advanced imaging, indicating an expanding market share in high-end medical services and enhancing future revenue potential.
- Strong Cash Flow and Financial Health: By the end of Q1, RadNet reported $455.3 million in cash and reduced DSO to a record low of 29.5 days, showcasing exceptional performance in liquidity management and financial health, providing ample funding for future investments.
- Rapid Growth in Digital Health: The Digital Health segment achieved $97 million in annual recurring revenue (ARR), representing a 95% year-over-year growth, with expectations to exceed $140 million by year-end, indicating significant progress in the company's strategic positioning in digital healthcare.
See More
RadNet (RDNT) Q1 2026 Earnings Transcript
See More
RadNet Reports Strong Q1 Results with Revised 2026 Outlook
- Significant Revenue Growth: RadNet reported net revenues of $576.63 million in Q1 2026, a substantial increase from $471.40 million in the same quarter last year, indicating strong demand and market expansion in the diagnostic imaging sector.
- Narrowing Losses: The company recorded a net loss of $24.73 million, or $0.43 per share, in Q1 2026, which is an improvement compared to a loss of $29.74 million, or $0.51 per share, in Q1 2025, suggesting progress in cost control and operational efficiency.
- Improved EBITDA: Adjusted EBITDA reached $63.26 million, up from $46.40 million a year earlier, reflecting ongoing enhancements in profitability and operational efficiency within the company.
- Optimistic 2026 Outlook: RadNet expects revenues to range between $2.355 billion and $2.405 billion for 2026, a significant increase from $2.040 billion in 2025, while adjusted EBITDA is projected to be between $340 million and $353 million, highlighting strong future growth potential.
See More
RadNet Reports Strong Q1 2026 Financial Results with 22.1% Revenue Growth
- Significant Revenue Growth: In Q1 2026, RadNet achieved total revenue of $575.6 million, reflecting a 22.1% year-over-year increase, primarily driven by a rebound in advanced imaging procedural volumes, showcasing the company's strong recovery capabilities in the market.
- Digital Health Segment Outperformance: The Digital Health segment reported a 51.5% increase in revenue to $29.1 million, although Adjusted EBITDA decreased to $1.3 million, indicating that ongoing investments in digital transformation are yielding positive results despite short-term challenges.
- Substantial EBITDA Improvement: The Adjusted EBITDA for Q1 2026 reached $63.3 million, a 36.3% increase compared to the same period last year, reflecting significant enhancements in operational efficiency and cost control, which bolster expectations for future profitability.
- Optimistic Future Outlook: RadNet revised its Imaging Center guidance for 2026, anticipating further growth in revenue and free cash flow, demonstrating confidence in future market demand, particularly through its partnership with Trinity Health, which will further drive the implementation of digital health solutions.
See More
Alpha Wave Global Reduces RadNet Stake by 63,147 Shares
- Stake Reduction Details: According to an SEC filing dated May 14, 2026, Alpha Wave Global reduced its RadNet position by 63,147 shares in Q1, with an estimated trade value of approximately $4.31 million, indicating a cautious outlook on the company.
- Ownership Proportion Change: Following the reduction, Alpha Wave Global's stake in RadNet stands at 478,304 shares, representing 3.38% of its 13F AUM, reflecting a diminished confidence in the company's future performance.
- Financial Performance Overview: RadNet's latest earnings report indicates a 22.1% year-over-year revenue increase to $575.6 million, with adjusted EBITDA rising 36.3% to $63.3 million, showcasing strong growth potential in its imaging business.
- Market Performance Analysis: As of May 13, 2026, RadNet shares were priced at $52.98, down 12.5% over the past year, significantly underperforming the S&P 500 by 38.9 percentage points, prompting investors to closely monitor its future market performance.
See More
RadNet Hosts Free Webinar on Men's Health Issues
- Focus on Men's Health: RadNet will host a free webinar on June 13, 2026, aimed at raising public awareness about significant men's health issues, particularly coronary artery disease, prostate cancer, and lung cancer, which pose major threats to American men's health.
- Disease Statistics: Heart disease remains the leading cause of death among American men, with over 52% of men over 20 living with some form of cardiovascular disease, while prostate cancer affects 1 in 8 men, with more than 50% of the risk linked to genetics.
- Importance of Early Screening: The webinar will emphasize the critical role of early detection in improving health outcomes, recommending that men start screening for heart disease at age 40, prostate cancer at 45, and lung cancer at 50 to identify potential health issues promptly.
- Expert Speaker Lineup: The event will feature presentations from several medical experts, including Dr. Michael G. Coords, Medical Director in California, Dr. Randall Stenoien, Medical Director in Texas, and Dr. Evan Kaminer, Medical Director in New York, who will share the latest advancements and technologies in their respective fields to help participants better understand men's health issues.
See More
RadNet Reports Record Q1 2026 Earnings Amid Weather Challenges
- Record Performance: RadNet achieved record revenue and adjusted EBITDA in Q1 2026, despite an estimated $13 million revenue and $9 million EBITDA loss due to severe weather, demonstrating the company's resilience and sustained market demand even in challenging conditions.
- Significant Procedure Growth: PET/CT procedures increased by 35.2% year-over-year, with same-center growth of 14.7%, and 29.3% of procedural volume coming from advanced imaging, indicating an expanding market share in high-end medical services and enhancing future revenue potential.
- Strong Cash Flow and Financial Health: By the end of Q1, RadNet reported $455.3 million in cash and reduced DSO to a record low of 29.5 days, showcasing exceptional performance in liquidity management and financial health, providing ample funding for future investments.
- Rapid Growth in Digital Health: The Digital Health segment achieved $97 million in annual recurring revenue (ARR), representing a 95% year-over-year growth, with expectations to exceed $140 million by year-end, indicating significant progress in the company's strategic positioning in digital healthcare.
See More
RadNet (RDNT) Q1 2026 Earnings Transcript
See More
RadNet Reports Strong Q1 Results with Revised 2026 Outlook
- Significant Revenue Growth: RadNet reported net revenues of $576.63 million in Q1 2026, a substantial increase from $471.40 million in the same quarter last year, indicating strong demand and market expansion in the diagnostic imaging sector.
- Narrowing Losses: The company recorded a net loss of $24.73 million, or $0.43 per share, in Q1 2026, which is an improvement compared to a loss of $29.74 million, or $0.51 per share, in Q1 2025, suggesting progress in cost control and operational efficiency.
- Improved EBITDA: Adjusted EBITDA reached $63.26 million, up from $46.40 million a year earlier, reflecting ongoing enhancements in profitability and operational efficiency within the company.
- Optimistic 2026 Outlook: RadNet expects revenues to range between $2.355 billion and $2.405 billion for 2026, a significant increase from $2.040 billion in 2025, while adjusted EBITDA is projected to be between $340 million and $353 million, highlighting strong future growth potential.
See More
RadNet Reports Strong Q1 2026 Financial Results with 22.1% Revenue Growth
- Significant Revenue Growth: In Q1 2026, RadNet achieved total revenue of $575.6 million, reflecting a 22.1% year-over-year increase, primarily driven by a rebound in advanced imaging procedural volumes, showcasing the company's strong recovery capabilities in the market.
- Digital Health Segment Outperformance: The Digital Health segment reported a 51.5% increase in revenue to $29.1 million, although Adjusted EBITDA decreased to $1.3 million, indicating that ongoing investments in digital transformation are yielding positive results despite short-term challenges.
- Substantial EBITDA Improvement: The Adjusted EBITDA for Q1 2026 reached $63.3 million, a 36.3% increase compared to the same period last year, reflecting significant enhancements in operational efficiency and cost control, which bolster expectations for future profitability.
- Optimistic Future Outlook: RadNet revised its Imaging Center guidance for 2026, anticipating further growth in revenue and free cash flow, demonstrating confidence in future market demand, particularly through its partnership with Trinity Health, which will further drive the implementation of digital health solutions.
See More
